English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Little is known regarding the dynamics of antibody and T-cell responses in chronic kidney disease (CKD) following COVID-19 vaccination. Material and methods Prospective observational cohort study including 144 participants on hemodialysis (HD) (n = 52), peritoneal dialysis (PD) (n = 14), kidney transplantation (KT) (n = 30) or advanced chronic kidney disease not on dialysis (ACKD), and healthy controls (n = 18). Anti-Spike(S) antibody and T-cell responses were assessed at 15 days (15D) and 3 months (3M) after complete vaccination schedule. HD, PD and KT patients received mRNA vaccines (mRNA-123 and BNT162b2). Most ACKD patients received BNT162b2 (n = 23), or Ad26.COV.2.S (4). Most controls received BNT162b2 (n = 12), or Ad26.COV.2.S (n = 5). Results Anti-S antibodies at 15D and 3M were detectable in 95% (48/50)/98% (49/50) of HD patients, 93% (13/14)/100% of PD patients, 67% (17/26)/75% (21/28) of KT patients and 96% (25/26)/100% (24/24) of ACKD patients. Rates for healthy controls were 81% (13/16)/100% (17/17). Previous SARS-CoV-2-S infection was documented in 4 (7,7%) HD patients, 2 (14,3%) PD patients, 2 (6,7%) KT patients, 1 (5,55%) healthy controls and in no ACKD patient. Antibody levels decreased at 3M in HD (p = 0.04), PD (p = 0.008), and ACKD patients (P = 0.0009). In KT patients levels increased (P = 0.04) between 15D and 3M,  although they were low at both time points. T-cell responses were detected in HD patients in 37 (80%) at baseline, 35 (70%) at 15 days and 41 (91%) at 3 months. In PD patients, T-cell responses appeared in 8 (67%) at baseline, 13 (93%) at 15 days and 9 (100%) at 3 months. In KT patients, T-cell responses were detected in 12 (41%) at baseline, 22 (84%) at 15 days and 25 (96%) at 3 months.In ACKD patients, T-cell responses were detected in 13 (46%) at baseline, 20 (80%) at 15 days and 17 (89%) at 3 months. None of healthy controls showed T-cell response at baseline, 10 (67%) at 15 days and 8 (89%) at 3 months. Conclusions Most HD, PD and ACKD patients develop SARS-CoV-2-S antibody responses comparable to that of healthy controls, in contrast to KT recipients. Antibody waning at 3M was faster in HD, PD, ACKD patients. No differences in SARS-CoV-2 T-cell immunity responses were noticed across study groups.

Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within 3 months after COVID-19 full vaccination